tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dermatomycoses D003881 17 associated lipids
Dermatomyositis D003882 2 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Digestive System Diseases D004066 3 associated lipids
Down Syndrome D004314 18 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Dyspnea D004417 10 associated lipids
Earache D004433 2 associated lipids
Echinostomiasis D004451 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Eczema D004485 4 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Epididymitis D004823 1 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Erythema D004890 22 associated lipids
Erythema Nodosum D004893 5 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythroplasia D004919 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Exanthema D005076 11 associated lipids
Eye Diseases D005128 12 associated lipids
Facial Dermatoses D005148 7 associated lipids
Facial Neoplasms D005153 3 associated lipids
Fatigue D005221 10 associated lipids
Fatty Liver D005234 48 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Folliculitis D005499 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Foot Dermatoses D005533 3 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Castleman Disease D005871 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Gingivitis D005891 3 associated lipids
Glioma D005910 112 associated lipids
Gliosis D005911 6 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Glycosuria D006029 10 associated lipids
Gout D006073 4 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Graves Disease D006111 6 associated lipids
Gynecomastia D006177 6 associated lipids
Hallucinations D006212 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hand Injuries D006230 1 associated lipids
Headache D006261 4 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Failure D006333 36 associated lipids
Heart Injuries D006335 6 associated lipids
Hematologic Diseases D006402 3 associated lipids
Hematoma D006406 5 associated lipids
Hematuria D006417 13 associated lipids
Hemolysis D006461 131 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Hemophilia A D006467 10 associated lipids
Hemorrhage D006470 15 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Hepatitis C D006526 7 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Ventral D006555 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Herpesviridae Infections D006566 4 associated lipids
HIV Seropositivity D006679 15 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hydronephrosis D006869 4 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperglycemia D006943 21 associated lipids
Hyperkalemia D006947 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Yoshimura N et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. 1989 Transplant. Proc. pmid:2468202
Thomson AW et al. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. 1989 Transplant. Proc. pmid:2468203
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Kay JE et al. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. 1989 Immunology pmid:2475433
Moriyama S [Experimental tracheal reconstruction by allotransplantation]. 1989 Nihon Kyobu Geka Gakkai Zasshi pmid:2475555
Freedman RB Immunosuppression. Convergence of drug action. 1989 Nature pmid:2477712
Siekierka JJ et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. 1989 Nature pmid:2477714
Harding MW et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 1989 Nature pmid:2477715
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Yamamoto K et al. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. 1990 Immunology pmid:1689694
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Ericzon BG et al. Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. 1990 Transplant. Proc. pmid:1689905
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Suzuki N et al. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. 1990 Clin. Exp. Immunol. pmid:1690097
McCauley J et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. 1990 Lancet pmid:1690326
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Standaert RF et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. 1990 Nature pmid:1696686
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Deguchi K et al. [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. 1990 No To Shinkei pmid:1697182
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Hara S et al. The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. 1990 Clin. Immunol. Immunopathol. pmid:1700936
Murase N et al. Effect of FK 506 on spontaneous diabetes in BB rats. 1990 Diabetes pmid:1700959
Kawashima H and Mochizuki M Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. 1990 Exp. Eye Res. pmid:1701148
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Arita C et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. 1990 Clin. Exp. Immunol. pmid:1702374
Woo J et al. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. 1990 Clin. Exp. Immunol. pmid:1702375
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242